Sutro Biopharma is at the forefront of developing innovative cancer therapeutics through its advanced technologies, particularly its cell-free expression platform. This platform enables the rapid and precise design of next-generation antibody-drug conjugates (ADCs) and bispecific antibodies. Sutro's unique approach allows for the incorporation of non-natural amino acids (nnAAs) at specific sites within antibodies, facilitating the creation of homogeneous ADCs with optimized therapeutic indices. This precision addresses the limitations of traditional ADCs, which often suffer from structural heterogeneity, thereby enhancing the predictability of pharmacokinetic properties and overall efficacy. The company’s innovative iADC design aims to deliver dual payloads directly to tumors, combining cytotoxic agents with immune-activating components to not only target cancer cells but also stimulate an immune response tailored to the patient's specific tumor.

In addition to ADCs, Sutro's technology supports the development of bispecific antibodies that can bind to two different antigens simultaneously. This capability allows for various therapeutic strategies, such as enhancing the binding affinity to target cells or increasing selectivity for diseased tissue over healthy tissue. Sutro's rapid expression and characterization processes enable the efficient screening of numerous antibody variants, optimizing critical factors like binding efficiency, spatial orientation, and stability. By leveraging these advanced technologies, Sutro Biopharma is committed to transforming cancer treatment and improving patient outcomes through innovative therapeutic solutions.

United States

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

Cancer

Immune System Diseases

Infectious Diseases

Sutro Biopharma

Platinum-resistant ovarian cancer

Novel homogeneous antibody drug conjugate (ADC) using precisely positioned non-natural amino acids.&nbsp;
 
Targets FolRα, which is overexpressed in certain cancers including ovarian cancer
Drug-antibody ratio of 4:1, with a proprietary cleavable hemiasterlin linker-warhead that is stable in circulation.
 
Internalization of the ADC releases hemiasterlin in the tumor cell, resulting in immunogenic cell death of cancer cells.

Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC)

Acute myeloid leukemia

Non-small cell lung carcinoma

Luveltamab tazevibulin, abbreviated as “luvelta” and formerly known as STRO-002, is a FRα-targeting antibody-drug conjugate (ADC) designed to treat a broad range of patients with ovarian cancer, including those with lower FRα-expression who are not eligible for approved treatment options targeting FRα. Developed and manufactured with Sutro’s cell-free XpressCF® platform, luvelta is a homogeneous ADC with four hemiasterlin cytotoxins per antibody, precisely positioned to efficiently deliver to the tumor while ensuring systemic stability after dosing. REFRαME-O1, a Phase 2/3 registration-directed study for patients with platinum-resistant ovarian cancer is ongoing. The Company has additional ongoing trials in patients with endometrial cancer, non-small cell lung cancer, and in combination with bevacizumab in patients with ovarian cancer. The Company expects to initiate REFRαME-P1, a Phase 2/3 registration-directed study for patients with CBF/GLIS2 acute myeloid leukemia, a rare subtype of pediatric cancer, in the second half of 2024. The U.S. Food and Drug Administration (FDA) has granted luvelta a Fast Track designation for Ovarian Cancer, as well as Orphan and Rare Pediatric Disease designations for CBF/GLIS2 Pediatric AML.

Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC) 

Endometrial cancer

Ovarian cancer

Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC) + bevacizumab

Esophageal cancer

Solid tumor/s

M1231 (MUC1-EGFR Bispecific ADC) 

B-cell lymphoma

Follicular lymphoma

Lymphoma

Mantle cell lymphoma

STRO-001 is a novel homogeneous antibody-drug conjugate (ADC) using precisely positioned non-natural amino acids
Comprises two non-cleavable maytansinoid linker-warheads (DAR=2) that are stable in circulation
The active warhead derivative efficiently kills tumor cells following internalization of the ADC and was designed to minimize bystander effects

Sutro Biopharma

Company Details